Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-2 brigimadlin in MDM2-amplified TP53 wild-type advanced solid tumors
jRCT2031220405Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of brigimadlin in biliary adenocarcinoma, pancreatic adenocarcinoma (PDAC), Non-small cell lung cancer adenocarcinoma (NSCLC) and 2 more, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response. Started Nov 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
biliary adenocarcinomapancreatic adenocarcinoma (PDAC)Non-small cell lung cancer adenocarcinoma (NSCLC)transitional cell carcinoma of the bladder (TCC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031220405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220405.